aTyr Pharma (ATYR) vs Quince Therapeutics (QNCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
aTyr Pharma (ATYR) has outperformed Quince Therapeutics (QNCX) over the past year, losing 74.5% versus a loss of 92.4%. Over five years, ATYR leads with a -97.1% price change compared with -99.8% for QNCX. Quince Therapeutics is the larger company by market cap ($30.9 million vs $25.4 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATYR | QNCX |
|---|---|---|
| Share price | $0.2591 | $30.35 |
| Market cap | $25.41M | $30.87M |
| 1-day change | +1.49% | +3.43% |
| YTD return | -67.39% | -95.62% |
| 1-year return | -74.47% | -92.35% |
| 5-year return | -97.07% | -99.77% |
| EPS (TTM) | $-0.62 | $-214.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.12 | $910.00 |
| 52-week low | $0.25 | $15.10 |
| Distance from 52-week high | -76.87% | -96.66% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +1003.82% | +148.53% |
| Average volume | 3.24M | 28.83K |
| Shares outstanding | 98.09M | 1.02M |
| Employees | 58 | 38 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATYR has outperformed QNCX by 17.9 percentage points over the past year.
About aTyr Pharma
ATYR stock →aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 58 employees
About Quince Therapeutics
QNCX stock →Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees
ATYR vs QNCX FAQ
Which is bigger, aTyr Pharma or Quince Therapeutics?
Quince Therapeutics (QNCX) is larger, with a market capitalization of $30.87M compared with $25.41M for aTyr Pharma (ATYR).
Which stock has performed better over the past year, ATYR or QNCX?
ATYR returned -74.47% over the past 12 months, compared with -92.35% for QNCX (price return, excluding dividends). Past performance does not predict future results.
Are aTyr Pharma and Quince Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.